A basal left ventricular thrombus rapidly progressed in size despite triple antithrombotic therapy including Apixaban following acute coronary syndrome.
Case Report (n=1)
Does triple antithrombotic therapy including apixaban prevent left ventricular thrombus progression after myocardial infarction?
Direct oral anticoagulants like apixaban may fail to prevent the progression of left ventricular thrombus following myocardial infarction, highlighting the need for individualized therapy and short-term imaging follow-up.
Background and Clinical Significance: Left ventricular thrombus formation after acute coronary syndrome represents a severe complication. Comprehensive echocardiographic assessment of the entire ventricle is essential, as regional wall motion abnormalities predispose to thrombus development. Although vitamin K antagonists have traditionally been the cornerstone of therapy, the convenience of direct oral anticoagulants has made them increasingly popular. However, the paucity of prospective data raises concerns regarding their general interchangeability. Case Presentation: We present a case of a basal left ventricular thrombus that rapidly progressed in size despite triple antithrombotic therapy including Apixaban. Conclusions: Following ACS, regional LV dysfunction predisposes to LVT formation—even in patients with only mild to moderate systolic impairment or non-apical akinesia. Although rare, LVT may also develop in basal and mid-ventricular segments. Anticoagulant selection should remain individualized, and short-term follow-up imaging is necessary to monitor therapeutic response.
Merz et al. (Mon,) conducted a case report in Left ventricular thrombus after myocardial infarction (n=1). Apixaban (as part of triple antithrombotic therapy) was evaluated on Left ventricular thrombus progression. A basal left ventricular thrombus rapidly progressed in size despite triple antithrombotic therapy including Apixaban following acute coronary syndrome.